Analysis · Market and data

NAD supplement in the EU: what is allowed, what is not, and what a US brand can sell in Poland

NAD+ is one of the biggest supplement themes in the US and a near-empty one in Poland. Most of that gap is legal, not cultural. Here is the status of each ingredient, with the EU text behind it.

Published 11 November 2026Reading time 11 minAuthor

Short answer

A NAD supplement sold in Poland has to be built on ingredients that EU law allows. Nicotinamide riboside chloride (NR) is an authorised novel food for food supplements, up to 300 mg/day for adults, and a listed source of niacin. NMN has been confirmed as a novel food and, as of 29 October 2026, we found no authorisation adding it to the Union list, so it cannot be sold. NAD+ itself (nicotinamide adenine dinucleotide) is listed in the Commission's Novel Food status Catalogue as not novel in food supplements; NADH has no separate entry. Polish search demand for the theme is about one-fourteenth of US demand per capita.

NAD supplement demand: Poland vs the US

Start with demand, because it shapes how much a launch is worth. In Google Ads Keyword Planner, average monthly searches, October 2025 - September 2026, the English query was searched from the US about 90,500 times a month, and the Polish query from Poland about 720 times.

QueryUS (monthly)Poland (monthly)Per-capita index PL vs US
NAD supplement90,5007200.07
NMN60,5005,4000.81

The index divides each country's searches by its population (37 million for Poland, 335 million for the US) and compares them. At 0.07, a Pole searches for NAD supplements at roughly 7% of the rate of an American. NMN, interestingly, is close to parity at 0.81, even though it cannot be sold legally as a food in the EU (see below). People in Poland search for the ingredient they read about; they do not search for the umbrella term.

Read this as a white space with a legal fence around it. The demand that exists is ingredient-led, so a product that cannot say "NMN" on the pack has to earn its own search traffic.

NMN, NR and NAD+ supplements in Europe: status at a glance

IngredientEU status (as of 29 October 2026)Legal basis we checkedCan you sell it in Poland as a food supplement?
Nicotinamide riboside chloride (NR)Authorised novel food; listed niacin sourceImplementing Reg. (EU) 2020/16 and 2022/1160; Reg. (EU) 2021/418Yes, within the conditions of use
Nicotinamide (vitamin B3)Permitted vitamin formDirective 2002/46/EC, Annex IIYes, as niacin
Nicotinic acid (vitamin B3)Permitted vitamin formDirective 2002/46/EC, Annex IIYes, as niacin
Nicotinamide mononucleotide (NMN)Novel food (Art. 4 consultation, 2022); no Union list entry foundReg. (EU) 2015/2283, Art. 6(2); Commission consultation outcomeNo
NAD+ (nicotinamide adenine dinucleotide)Not novel in food supplements (catalogue entry POL-NF-09841)Novel Food status Catalogue (non-binding)Yes, in food supplements only
NADH and other NAD formsNo separate catalogue entry foundNovel Food status CatalogueCheck the exact form first

The table covers the ingredient, not the dose or claims. Those come next.

Nicotinamide riboside EU status: authorised, with conditions

NR is the one NAD precursor with a clean EU route. Commission Implementing Regulation (EU) 2020/16 is the act "authorising the placing on the market of nicotinamide riboside chloride as a novel food" and adds it to the Union list (Implementing Regulation (EU) 2020/16). A later act amended the conditions of use and specifications and extended it to other food categories (Implementing Regulation (EU) 2022/1160).

For food supplements the conditions read: "300 mg/day for the adult population, excluding pregnant and lactating women" and "230 mg/day for pregnant and lactating women" (Implementing Regulation (EU) 2022/1160, Annex). The label must use the designation "nicotinamide riboside chloride". EFSA's underlying opinion found it "safe under the proposed conditions of use for the healthy adult population" (EFSA Journal, NR chloride opinion).

NR chloride is also a listed source of vitamin B3. Commission Regulation (EU) 2021/418 is titled as "amending Directive 2002/46/EC of the European Parliament and of the Council as regards nicotinamide riboside chloride" and adds it under niacin in Annex II (Regulation (EU) 2021/418). Annex II originally listed "(a) nicotinic acid" and "(b) nicotinamide" (Directive 2002/46/EC, Annex II).

One commercial point. The 2020 authorisation came with five years of data protection for the original applicant; the annex gives its end as "20 February 2025" (Implementing Regulation (EU) 2020/16, Annex). Check the current consolidated Union list entry on the day you file, because later amendments can add conditions.

NMN EU status: a novel food that is not authorised

The rule is simple. "Only novel foods authorised and included in the Union list may be placed on the market within the Union" (Regulation (EU) 2015/2283, Article 6(2)). A novel food is one "not used for human consumption to a significant degree within the Union before 15 May 1997" (Article 3(2)(a)).

NMN's status was settled through the formal consultation route. In a request to the Czech authorities, published by the Commission, the conclusion on NMN at 95-99% purity for food supplements was: "The ingredient is considered a novel food" (Consultation request on NMN, Czech Republic). The Commission's list of consultation outcomes records it as "Novel food", dated 11 October 2022 (Commission: consultation process on novel food status).

Where the applications stand

Several applications have been filed. The Commission's summaries list NMN files from 2023 (a notification), 2024 and 2025 (Commission: summary of applications and notifications). The 2024 application seeks use "as a food ingredient for use in food supplements" for adults at up to 500 mg/day (Summary of application 2024-27111). At the same time the Commission has twice ended NMN procedures: one decision in 2022 on beta-NMN and one in 2026 "terminating the procedure for authorising the placing on the market of nicotinamide mononucleotide (NF 2025/35790)" (Commission: decisions terminating the procedure).

You may read that EFSA has assessed an NMN application. We could not open an EFSA opinion on NMN, so its content is to be confirmed. Either way, an EFSA opinion is not an authorisation: after the opinion, the Commission "shall submit to the committee referred to in Article 30(1) a draft implementing act" (Regulation (EU) 2015/2283, Article 12(1)), and only the adopted act changes the Union list. If an authorisation comes, it may also carry data protection, under which protected data cannot be used for a later applicant "during a period of five years from the date of the authorisation of the novel food" (Article 26).

For a brand, the practical answer today is: no NMN in a product for Poland. Our page on novel food and maximum doses in Poland covers the general rules.

NAD+ and NADH supplements in Europe: what the catalogue says

The Commission's Novel Food status Catalogue lists nicotinamide adenine dinucleotide (entry POL-NF-09841, checked on 11 November 2026) as not novel in food supplements. That means NAD+ may be used in food supplements, but not in other foods, without a novel food authorisation. We found no separate entry for NADH. The catalogue is described by the Commission as "a non-binding tool" and "a non-exhaustive list" (Commission: Novel Food status Catalogue).

Absence of an entry is not permission. The burden sits with the operator: "Food business operators shall verify whether or not the food" falls within the novel food rules (Regulation (EU) 2015/2283, Article 4(1)), and where unsure "shall consult the Member State where they first intend to place the novel food" (Article 4(2)). The Commission page says the provisions of "Commission Implementing Regulation (EU) 2018/456 should be followed" (consultation process page).

For Poland, that means GIS. If NADH, a liposomal NAD form or another derivative is the hero ingredient of your US product, budget for a consultation, or reformulate before you file anything.

What a NAD+ product may say on a Polish label

EU claims law is stricter than US structure-function practice. "Health claims shall be prohibited unless they comply with the general requirements in Chapter II" and are authorised and listed (Regulation (EC) No 1924/2006, Article 10(1)). Phrases such as "NAD+ booster", "cellular energy" or "healthy ageing" do not come from the authorised list; check any wording against the EU Register before you use it.

What is on the list is niacin. The authorised claims include "Niacin contributes to normal energy-yielding metabolism" and "Niacin contributes to the reduction of tiredness and fatigue", among six niacin claims (Regulation (EU) No 432/2012, Annex). The condition is that the food is at least a source of niacin, which "may only be made where the product contains at least a significant amount" as defined in EU law (Regulation (EC) No 1924/2006, Annex).

Whether the niacin content can be counted from NR chloride for the "source of" threshold, and how to express it on the label, is a point to confirm with a food lawyer before artwork. Our guide to health claims in Poland covers the claims rules in general.

What a US brand can actually sell in Poland

A typical US NAD+ range has three kinds of SKU: an NMN capsule, an NR capsule, and a "NAD+" or liposomal NAD product, often with resveratrol, pterostilbene or similar co-ingredients. Map each one before you plan the launch.

US SKUWhat to do for Poland
NMN capsuleDrop for now. Watch the Union list; do not pre-print packs.
NR capsuleViable. Check dose against 300 mg/day, the target group wording and the designation on the label.
NAD+ capsuleViable as a food supplement (catalogue: not novel in food supplements). Claims only from the authorised list.
NADH or liposomal NAD productHold. Check the exact form; consult GIS under the novel food rules or reformulate.
Multi-ingredient "NAD stack"Check every co-ingredient separately; one novel food stops the whole SKU.
  1. List every ingredient and its exact form. "Niacin" on a US label can be nicotinic acid, nicotinamide or something else. The EU status depends on the form.
  2. Check each form against the Union list and Annex II. Use the acts cited above and the consolidated text in force on the day.
  3. Recalculate doses for adults. NR chloride is capped at 300 mg/day for adults, with separate wording for pregnant and lactating women.
  4. Rewrite the claims from the authorised list. Replace "NAD+ booster" language with authorised niacin wording if the product qualifies.
  5. Write the Polish label. Designation, dose, warnings and the operator's name; see supplement label requirements in Poland.
  6. File the GIS notification before first sale. Process in GIS notification.

If your range was built for the US market and NMN is the bestseller, read US supplement brands entering the EU first: the NMN gap is one case of a wider pattern.

Sources

Primary legal texts and official pages used in this guide. Always read the consolidated version in force on the day you act.

  1. EU Novel Food status Catalogue - Nicotinamide adenine dinucleotide (POL-NF-09841) and NMN (POL-NF-00540)
  2. Regulation (EU) 2015/2283 on novel foods, Articles 3, 4, 6, 12, 26 - EUR-Lex
  3. Commission Implementing Regulation (EU) 2020/16 authorising nicotinamide riboside chloride - EUR-Lex
  4. Commission Implementing Regulation (EU) 2022/1160 amending conditions of use for nicotinamide riboside chloride - EUR-Lex
  5. Commission Regulation (EU) 2021/418 amending Directive 2002/46/EC as regards nicotinamide riboside chloride - EUR-Lex
  6. Directive 2002/46/EC on food supplements, Annex II - EUR-Lex
  7. Regulation (EC) No 1924/2006 on nutrition and health claims, Article 10 and Annex - EUR-Lex
  8. Commission Regulation (EU) No 432/2012, list of permitted health claims (niacin) - EUR-Lex
  9. EFSA Journal - Safety of nicotinamide riboside chloride as a novel food
  10. European Commission - consultation request on NMN novel food status (Czech Republic)
  11. European Commission - consultation process on novel food status
  12. European Commission - decisions terminating the procedure
  13. European Commission - summary of novel food applications and notifications
  14. European Commission - summary of application 2024-27111 (NMN)
  15. European Commission - Novel Food status Catalogue

This is not legal advice. Check the consolidated Union list and consult a food lawyer or GIS before you formulate or file.

Frequently asked questions

Is NMN legal in the EU?
As of 29 October 2026 we found no act adding NMN to the Union list of novel foods. NMN has been confirmed as a novel food, so it cannot be placed on the market as a food supplement until it is authorised.
What is the nicotinamide riboside EU status?
Nicotinamide riboside chloride is an authorised novel food for food supplements, up to 300 mg/day for adults excluding pregnant and lactating women. It is also a listed source of niacin in Annex II of Directive 2002/46/EC.
Can I sell a NAD supplement in Poland?
Yes, if it is built on permitted ingredients such as nicotinamide riboside chloride or permitted niacin forms, with a Polish label and a GIS notification. NAD+ is listed as not novel in food supplements; NMN-based products cannot be sold, and NADH or other NAD forms need a separate status check first.
Are NAD+ supplements in Europe allowed to claim anti-ageing effects?
Only authorised health claims may be used, and we know of no authorised anti-ageing claim for NAD precursors; check the EU Register. Niacin claims are available where the product is at least a source of niacin.
Does an EFSA opinion on NMN mean it is authorised?
No. After an EFSA opinion the Commission prepares a draft implementing act; only the adopted act adds a novel food to the Union list.
How do I check the status of NAD or NADH?
Search the Commission's Novel Food status Catalogue, then consult GIS under Article 4 of Regulation (EU) 2015/2283 if the status is unclear. The catalogue is non-binding.

Read next

Checklist · Law & labellingNovel food status and maximum doses in Poland: what to check before launchTwo questions decide whether your formula can enter Poland unchanged: is every ingredient allowed in food, and are your doses in line with Polish practice. Both are easy to check early and expensive to discover late.Guide · Market entryUS supplement brands entering the EU: what changes from DSHEAFDA registration, NDI status and the FDA disclaimer do not carry over. Here is what a US brand has to rebuild for Europe - and the legal texts on both sides.Guide · Law & labellingHealth claims for supplements in Poland and the EUHealth claims are where foreign supplement brands most often break EU law without noticing. The copy that sells in the US or the UK is frequently not allowed in Poland - on the label, on the website or in a creator's story.

US brand, EU plan? Start with the formula, not the sticker.

Send us your US label and formula. We will show you what has to change for the EU and for Poland before you commit stock.

Contact us